CLOs on the Move


 
Lygos employs cutting edge synthetic biology techniques to generate microbial catalysts to convert agricultural feedstocks into fine and commodity chemicals. Our robust high throughput screening and strain construction facilitates the rapid optimization of pathways to convert cheap and renewable feedstock to high value chemicals.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.lygos.com
  • 1249 Eighth Street
    Berkeley, CA USA 94710
  • Phone: 510.356.0555

Executives

Name Title Contact Details
Photon Rao
Vice President of Legal Affairs Profile

Similar Companies

Osage Bio Energy

Osage Bio Energy is a Glen Allen, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Main OfficeReaction Design

Main OfficeReaction Design is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

CinRx Pharma

CinRx Pharma is a multi-asset biotech company focusing on advancing novel therapeutics that address large unmet medical needs.

Cognate BioServices

Cognate BioServices is a leading contract development and manufacturing organization specialized in cell and cell-mediated gene therapies. We pride ourselves in the level of quality and experience we bring to the table. Cognate is a dynamic, results-driven, organization focused on providing the broadest range of commercialization services to regenerative medicine, cellular immunotherapy and advance cell therapy companies, organizations and institutions. Cognate provides a unique combination of custom services to companies across all points of clinical and commercial development ranging from early preclinical studies, to mid phase trials and product scale-up though later stage clinical trials and bridging into commercial manufacturing. Cognate applies the know-how and expertise of its business, scientific and technical teams to successfully develop autologous and allogeneic products across multiple cell-based technology platforms from start to finish.

Atalanta Therapeutics

Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases. Our founders` groundbreaking discoveries in RNA interference offer a powerful therapeutic approach to halt diseases at their source.